

Management of rheumatoid arthritis in Poland – where daily practice might not always meet evidence-based guidelines

Bogdan Batko¹, Mariusz Korkosz², Anna Juś³, Piotr Wiland⁴

¹Department of Rheumatology, J. Dietl Specialist Hospital, Krakow, Poland

²Department of Rheumatology, Jagiellonian University Medical College, Krakow, Poland

³Medical Department, Roche Polska Sp. z o.o., Warsaw, Poland

⁴Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland

Submitted: 11 February 2019; **Accepted:** 25 March 2019

Online publication: 29 March 2019

Arch Med Sci 2021; 17 (5): 1286–1293

DOI: <https://doi.org/10.5114/aoms.2019.84092>

Copyright © 2019 Termedia & Banach

Corresponding author:

Bogdan Batko MD, PhD

Department

of Rheumatology

J. Dietl Specialist

Hospital

1 Skarbowa St

31-121 Krakow, Poland

Phone: +48 665 766 366

E-mail: bpbatko@gmail.com

Abstract

Introduction: International recommendations are intended to help rheumatologists in the effective management of rheumatoid arthritis (RA) through an evidence-based approach. This research aimed to evaluate management patterns and associated difficulties encountered by rheumatologists in daily practice.

Material and methods: Interviewers recruited 101 Polish rheumatologists in a random quota-based, nationwide sample of outpatient clinics. Quantitative data were input online using a computer-assisted web interview tool.

Results: Disease-modifying antirheumatic drugs (DMARDs) are not initiated at the time of diagnosis in 15% of RA patients, most often due to difficulties in patient-provider communication. The RA activity is assessed every 4 to 6 months by 30% of rheumatologists, and 64% of patients are reported to never achieve remission. Composite indices are the most reliable indicators of remission only for 38% of responders. Despite inadequate disease control with ≥ 2 treatment schedules with synthetic DMARDs, 34% of these patients are not considered for biological DMARDs (bDMARDs). Contraindications and reimbursement barriers are the most frequently stated reasons. Therapy with glucocorticoid (GC) lasting over 3 months is reported by 70% of rheumatologists. International recommendations are stated as the most common basis for treatment decisions.

Conclusions: Awareness of recommendations is not sufficient to ensure their application in clinical practice. Inadequate management of RA is quite prevalent, with a substantial contribution of non-medical factors. Daily practice mainly deviates from guidelines regarding frequency and mode of monitoring measures, time to DMARD initiation, and duration of GC treatment. Education programs and policy changes may significantly narrow the gap between evidence and practice.

Key words: antirheumatic agents, time-to-treatment, rheumatologists.

Introduction

Early studies have indicated that approximately half of patients receive the recommended care in chronic conditions, and this remains true when considering screening, diagnosis, treatment and follow-up [1].

Data regarding guideline adherence are important because they provide comparative benchmarks and identify potential areas of intervention [2]. In concordance with “treat-to-target” principles [3], evidence-based European League Against Rheumatism (EULAR) guidelines for rheumatoid arthritis (RA) advocate early and individualized treatment [4]. In comparison with routine care, tight control through more objective and frequent patient assessment was shown to improve clinical outcomes at little cost [5]. Rheumatologists are the assessors and the main decision makers when undertaking “tight control” to achieve remission, and their compliance with guidelines is of paramount importance. Sub-analyses of trials in RA have shown that physician adherence to tight control additively influences remission rates and working capacity [6]. In another recent trial, T2T adherence led to reduced disease activity and higher remission rates, while physician adherence was the only predictor of remission at 2-year follow-up [7]. Real-world studies have reported a considerable “evidence-practice” gap, with the majority of patients managed with inadequate disease control [8]. Research suggests that despite prior education and awareness of the “treat-to-target” (T2T) strategy, rheumatologists may still not fully comply in clinical practice [9, 10]. It has been suggested that time constraints, a shortage of specialists and budget limitations impede the application of T2T in real-world practice [11]. Potential barriers also include a lack of confidence in composite measures [12], and even poor patient-provider communication [13]. All these studies agree in that rheumatologists support T2T overall, but may not fully comply with particular recommendations, which is in line with multinational surveys [14]. In an Italian cross-sectional study, adherence to recommendations regarding methotrexate safety was good, while dosage and time of treatment initiation were suboptimal [15]. There are limited data regarding the practical challenges faced by rheumatologists in a real-world setting. The existing data are not easily comparable between countries due to health care system differences (financial and organizational), while Polish data are lacking. Potential interventions have to be tailored to national areas of unmet need, to the extent by which they are valued from a payer’s perspective. We previously characterized the epidemiology of RA in the first population-based study, which revealed an increased burden exceeding earlier projections, suboptimal control of disease and limited access to biologics [16]. This research was inductive, designed to describe the daily routine of Polish rheumatologists in the management of biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve patients with the RA diagnosis established at least 12 months earlier. Considering that only 3% of the Polish RA population have access to

bDMARDs [16], this population represents the vast majority of the RA population.

Material and methods

A representative sample of 101 Polish rheumatologists was recruited. Rheumatologists were invited in person by interviewers to answer an online questionnaire using computer-assisted web interviewing (CAWI).

Eligibility criteria for rheumatologist inclusion in the research were defined as follows:

- provision of care to at least 25 adult bDMARD-naïve RA patients, diagnosed at least 12 months earlier;
- initiation of non-biologic RA treatment in patients whom they managed from first-admission therapy.

Random quota sampling was used to select rheumatology outpatient care centers from a national database. All centers having a National Health Fund (NHF) contract for RA treatment, regardless of whether they provided biologic treatment or not, were included. The sample was allocated across different layers. These were defined by geographical distribution (division into voivodeships and city type), and the size of the NHF contract (3 groups of centers equal in size), and corresponded to the distribution of rheumatology centers. Based on these layers, 100 centers were randomly selected (the target sample size), and the starting points, the first places the interviewers went to invite rheumatologists to participate, were chosen. For each randomly selected starting point, a list of substitute centers was arranged in its geographical proximity. Geographical proximity was determined based on postal codes.

After all selected centers and substitute centers were included, sampling was carried out by quota, irrespective of established layers. This type of selection was necessary for 30% of the sample due to lack of consent. All data collected during the research were declarative, including prevalence estimates. Twenty-eight specialists were otherwise employed in centers offering reimbursement programs for bDMARDs. No data from the patients’ medical records were collected and no additional diagnostic or therapeutic interventions were involved. For the purpose of the research, rheumatologists were provided with a paper survey and an electronic questionnaire, available online. Interviews were completed from 16 November 2017 to 20 December 2017.

The questionnaire consisted of five parts. The first included 12 questions describing the clinical profile of patients. Data gathered involved e.g., the frequency of visits to the rheumatologist, the impact of the disease on the professional activity of the patients, and the criteria used for assessing

disease activity. The second part of the questionnaire focused on general issues associated with RA treatment, and contained 34 questions. The third part, including 28 questions, was dedicated to the analysis of RA therapy-related general practice with particular medications or treatment regimens. The fourth part dealt with reasons for withdrawal of selected medications, and contained 12 questions. The last part of the questionnaire assessed rheumatologists' opinions on the usage of glucocorticoids in addition to non-biologic RA treatment in 5 questions.

Results

The survey results describe rheumatologist statements regarding management of bDMARD-naïve patients with an RA diagnosis established at least 12 months earlier. Differences between clinical practice and EULAR recommendations are summarized in Table I.

Disease activity assessment

Rheumatologists estimated disease activity in patients with first-admission treatment to be high in 43%, moderate in 41% and low in 16%. Disease activity was assessed every 2–3 months by 62% of rheumatologists and monthly by 5% of specialists. Thirty percent of rheumatologists measure disease activity every 4–6 months.

The RA activity was most often assessed using the swollen and tender joint count (SJC/TJC) (92–93%) and physical examination (87%). Of the composite indices, the 28-joint disease activity score based on erythrocyte sedimentation rate (DAS28-ESR) was more commonly applied than the score based on C-reactive protein (CRP) (86% and 50%, respectively). In addition, 4–5% of rheumatologists used the simplified and clinical disease activity indices (SDAI, CDAI). Measures of disease activity are described in detail in Figure 1.

When determining remission, rheumatologists considered the following as the strongest indicators: SJC/TJC (46%), normalized ESR and CRP (43%), and DAS28 < 2.6 (38%). Of the rheumatologists who confirmed the use of ESR, 67% stated that it does not determine disease activity by itself. The same claim was made by 60% of rheumatologists for both CRP and Patient Global Assessment (PGA). Forty-two percent of rheumatologists use ultrasound (US) when assessing disease activity.

Conventional therapy in bDMARD-naïve patients

No treatment was initiated at the time of diagnosis in 15% of patients, for 29% of whom treatment commencement was delayed for over 3 months. Lack of patient consent/cooperation (69%) and long waiting queues for rheumatolo-

Table I. Nonconformity with EULAR recommendations in clinical practice in Poland

EULAR recommendations for RA patients	Declarative estimates as stated by rheumatologists	
	Inconsistency in applying recommendations in practice	Mean % patients
Therapy with csDMARDs should be started as soon as the diagnosis of RA is made	Treatment not initiated at diagnosis	15
	Lag time in treatment initiation from diagnosis (> 3 months)	29
Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient	Never achieving remission	64
	Time to first-ever remission (> 6 months)	54
	Sustained remission (> 12 months)	19
Monitoring should be frequent in active disease (every 1–3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted	Interval of disease activity monitoring (> 3 months)	33
MTX should be part of the first treatment strategy	Lack of MTX use in monotherapy or in combination with GC and/or other csDMARDs	10–12
Short-term glucocorticoids should be considered when initiating or changing csDMARDs, in different dose regimens and routes of administration, but should be tapered as rapidly as clinically feasible	GC treatment time (> 6 months)	25
If the treatment target is not achieved with the first csDMARD strategy, when poor prognostic factors are present, addition of a bDMARD or a tsDMARD should be considered; current practice would be to start a bDMARD	No bDMARD treatment planned (despite active disease after ≥ 2 treatment schemes/drugs)	34
	Referred for bDMARD treatment (active disease only after ≥ 3 treatment schemes/drugs)	51




Figure 1. Measures of RA activity used by rheumatologists in daily practice (n = 101)




Figure 2. Reasons for delay in treatment initiation from diagnosis (n = 78)


gist appointments (46%) were the most frequently reported reasons (described in detail in Figure 2).

Sixty-four percent of bDMARD-naïve patients have never achieved remission. The time to first-ever remission was over 6 months from treatment initiation for 54% of patients, and only 17% achieved remission in less than 3 months. Among patients who experienced 2 or more switches of treatment schedules, 30% did not achieve remission. Of the latter, 34% did not have treatment with biological agents planned. Most difficulties in enrolling patients for biologic therapy are due to non-medical factors, and among them contraindications to bDMARDs (39%) and reimbursement barriers (26%) are the most common (for further details see Figure 3).

The classical synthetic DMARDs (csDMARDs) most frequently prescribed by rheumatologists, regardless of time from diagnosis, were methotrexate (MTX) (100%), sulfasalazine (92%), and leflunomide (89%). Rheumatologists judged MTX to have the highest efficacy in achieving remission.

Among csDMARDs, the proportion of patients who did not achieve remission was 34% for MTX (lowest for all drugs, data not shown), 43% for leflunomide, and 59% for sulfasalazine. An MTX dosage of 25 mg/week was the most frequent (73%) highest dose in monotherapy. At this point, rheumatologists consider it an insufficient response and change therapy.

The MTX was included in 98% of first-treatment options: 81% commence with oral MTX and 17% with subcutaneous MTX. The first-line strategies most frequently applied were: oral MTX monotherapy (35%), oral MTX + glucocorticoids (GC) (19%), and oral MTX + GC + nonsteroidal anti-inflammatory drugs (19%). Rheumatologists estimated the proportion of patients to achieve remission at 56%, 66% and 61% respectively. MTX was excluded as a first-line therapy most often due to contraindications (49%) and low disease activity (21%). Second-line treatments most commonly comprised leflunomide, subcutaneous MTX, and sulfasalazine. Most rheumatologists



RA – rheumatoid arthritis, EULAR – European League Against Rheumatism, csDMARD/bDMARD/tsDMARD – classical synthetic/biological/targeted synthetic disease-modifying antirheumatic drug, GC – glucocorticoids, MTX – methotrexate.

Figure 3. Impediments to qualifying patients for biologic therapy despite active disease following 2 therapy modifications (n = 74)

estimated that the mean time of inadequate response before they switch therapy is 3–6 months (49%), while 19% stated 6–12 months.

Seventy percent of rheumatologists declared that the therapeutic use of GC lasts > 3 months and > 6 months for every fourth patient. Thirty percent of responders use GC therapy for 1–3 months.

The most common reasons reported for GC use duration > 3 months were lack of remission and disease activity increase despite DMARD treatment (40% and 38%, respectively). An estimated 72% of patients taking GC receive doses ≤ 7.5 mg/day, and 42% receive ≤ 5 mg/day.

The most common sources of reference for rheumatologists regarding RA management were the EULAR and ACR guidelines, personal experience, and scientific publications, in that order.

Clinical and productivity-oriented outcomes

Rheumatologists estimated that, at present, the majority (44%) of their bDMARD-naïve patients are characterized by inadequate disease control, with only 21% in sustained remission.

The general symptoms most often reported by patients include fatigue (55%), mood disturbances (33%), and anemia (32%). Long-lasting concomitant treatment for other comorbidities was estimated to be prescribed in almost 60% of patients, including osteoporosis treatment and cardiovascular disease prophylaxis (68% and 36%, respectively).

Sixty-five percent of rheumatologists estimate that the mean annual sick leave is 6–30 days, and 29% considered that RA does not limit their patients' work ability.

Discussion

The present research provides a unique and wide scope of insights into the management pat-

terns of RA, in which it may serve as a benchmark and provide a basis for tailored interventions. To our knowledge, we have provided the first representative Polish data on routine care of RA from a provider's viewpoint. We describe several areas of practice where nonadherence to guidelines may occur. There remains a considerable proportion of patients with inadequately controlled RA, in whom management may not be optimal, while a variety of medical and nonmedical challenges still exist.

Initiation of DMARD therapy once a diagnosis is established and the achievement of remission within the first 6 months are the cornerstones of RA management [4, 17, 18]. Indeed, achieving clinical remission by established indices has been demonstrated to improve radiographic and clinical outcomes in early RA [19]. Rheumatologists participating in a multinational survey were reported to prescribe a DMARD within 4 weeks of diagnosis in 67% of patients [9]. A pooled analysis of international data showed that the median lag time from diagnosis to DMARD initiation was 2.14 months (range: 0–2.2) [20]. In the context of our current findings, rheumatologists estimated that, on average, 85% of patients are assigned treatment at the time of diagnosis while of the remaining, 1/3 have a delay of over 3 months. Previous studies published in 2017 demonstrated that only 30% of patients in Poland are diagnosed within 3 months of symptom onset, while the average delay for the country was estimated to be 9 months [16]. When considering the lag time from symptom onset to diagnosis, and then on to treatment, there remains a significant proportion of Polish patients excluded from the therapeutic "window of opportunity". Priority in further research should be given to establishing a nationwide strategy for patients to receive a diagnosis and treatment within this desirable interval, where most RA patients might benefit.

Patient and provider communication is often underappreciated, despite shared decision-making emphasized as an overarching EULAR principle, and meta-analyses demonstrating that poor communication decreases adherence rates [21]. In addition to long waiting queues, 69% of rheumatologists emphasize difficulty in obtaining patient consent or cooperation. Nevertheless, higher awareness of this issue should translate into an education framework for rheumatologists. Educational interventions have been demonstrated to reduce physician non-adherence [22]. In a review by Wabe *et al.*, medication side effects, comorbidities and persisting disease were among the factors associated with physician nonadherence to T2T [23]. We provide evidence that comorbidities and contraindications to RA-dedicated drugs are among the most prevalent reasons for delayed DMARD treatment. An example is the use of MTX in hematologic or hepatic abnormalities, which may be present at disease onset. It should be recognized that the waiting time for laboratory and imaging test results can also account for the delay.

Rheumatologists estimated that at present only 21% of bDMARD-naïve patients have adequate disease control ($\text{DAS28} \leq 2.6$). Similarly, previous cross-sectional data demonstrated that 26.1% of Polish patients are in remission, including 3% of all patients with RA treated with bDMARDs [16]. This suggests that rheumatologists are aware, at least in their own practice, of the scale of inadequate disease control in RA patients. Unfortunately, if remission less than 6 months from diagnosis is attained only by 46% of patients, it means we are failing in “treating to target”. Notably, 30% of patients treated with at least 2 different courses of therapy were estimated not to achieve remission and 34% of them do not have bDMARDs planned for future treatment. The latter finding is particularly worrying when considering that all responders stated that they rely on EULAR guidelines when making treatment decisions. Studies previously showed that declarative awareness does not determine clinical application, even with previous training [9]. Although we cannot exclude personal convictions, rheumatologists identified several non-medical difficulties in initiating bDMARD treatment: 26% stated reimbursement barriers, 15% described patient fear of bDMARDs, and 4% of specialists themselves had concerns about bDMARD safety profiles. The identification of these issues in the present research may prompt policy makers to institute systemic changes and rheumatologists to more thoroughly address patient doubts. Vermeer *et al.* concluded that T2T is a feasible strategy for daily clinical practice based on a cohort of RA patients [24]. Overall T2T adherence was observed in close to 70% of visits; however, discordance

was observed when rheumatologists did not agree with disease assessment indices. In 2011, an international survey revealed that rheumatologists agreed least with the frequency and composite index use when monitoring in accordance with guidelines [14]. In a survey among Canadian rheumatologists, some responders stated that tight control was unnecessary [12]. At present, although 62% of rheumatologists stated that they monitor patients every 2–3 months, the majority are reported to never achieve remission, which indicates inadequate management. Strikingly, only 5% of responders specified that they monitor disease activity monthly, despite 41% of patients reportedly having highly active RA at diagnosis. This may suggest a lack of compliance with the principle of “tight control” and monitoring every 1 to 3 months until remission is reached. In a EULAR congress survey [25], 68% of responders stated that treatment success and remission were measured through improvement in composite indices, and acute-phase reactants were among the most frequently evaluated disease measures. One-third of participants relied on their own judgment when assessing RA activity. In other countries, composite index use received less support than in international surveys, and was considered by some to be too complicated for daily practice [12]. In the United Kingdom, CRP assay was performed monthly in 60% of patients, while DAS-28 was assessed only in 25% [26]. In a Japanese survey, rheumatologists were found to have a tendency to interpret individual rather than composite measures, while reasons for not calculating DAS28 included time shortage and lack of staff [13]. For overall disease activity assessment, Polish rheumatologists seem to place the highest value in joint evaluation (TJC/SJC), with acute-phase markers and DAS28-ESR also frequently applied. However, when determining remission, reliance on $\text{DAS28} < 2.6$ as the strongest indicator was reported only by 38% of specialists. This is concerning because personal judgment may be less sensitive to subclinical disease activity, and composite indices may more precisely determine progression. Furthermore, if only 60–67% of specialists consider acute phase molecules as singularly unreliable determinants of disease activity, the remaining specialists may inadequately monitor and adjust therapy using ESR and/or CRP. The CDAI use by only 5% of rheumatologist is striking, especially since it was developed for simplicity in daily practice. However, similar challenges are prevalent internationally. Only 27% of Japanese rheumatologists use validated composite indices of remission as a target of treatment [13]. In the United Kingdom, outside of early arthritis centers, monthly CRP is assessed in 70% of patients while DAS28 is assessed only in 13% [26].

Of note is the relatively high proportion (42%) of responders using US as a disease activity measure in RA. This may indicate the rising number of rheumatologists skilled in performing US or having access to an office-based US machine. To an extent, US assessment may also bypass the need for laboratory testing, which may be more time-consuming.

Remarkably, 98% of reported first-line treatment schemes included MTX (81% oral, 17% subcutaneous), which is the currently recognized anchor drug. Although preference in the initiation form of MTX is not indicated in current guidelines, randomized trials report a potentially higher efficacy of the subcutaneous route [27]. In practice, rheumatologists seem to treat subcutaneous MTX monotherapy as the first modification to therapy (12%), though leflunomide use (17%) is more common. The most common first therapy modifications included leflunomide monotherapy, subcutaneous MTX and sulfasalazine. In both mono- and polytherapy, the target dose of 25 mg of MTX per week was estimated to be reached by most patients. When considering treatment schemes, rheumatologists seem to practice in accordance with EULAR guidelines. However, an area of inconsistency is long-term GC use. The GC schemes lasting over 6 months are reportedly applied in 25% of patients. However, GCs are recommended only for short-term use and with rapid dose reduction [4].

High disease burden is recognized to affect patient quality of life and productivity loss [28, 29]. We conclude that rheumatologists recognize the prevalence of systemic RA-related symptoms and comorbidity burden. Most specialists (65%) estimated that the mean annual time spent on sick leave is between 6 days and 1 month. In comparison, social insurance data show that RA patients require 2 episodes of sick leave on average, with a mean duration of 17 days, indicating that actual time spent on sick leave is closer to 1 month [29]. Rheumatologists may have underestimated this time period, since patients can request sick leave from their GPs and other specialists. To illustrate the importance of these estimates, seropositive RA was shown to be the most costly autoimmune disease to cause sick leave, which in itself contributes to about 40% of total RA costs, alongside disability [29].

The major limitation of the research is the survey design, which is based on individual claims. The findings were not compared with medical records; therefore they are based on the credibility of responses and associated bias. The wide scope of the investigation did not allow each aspect of management to be assessed critically, and can only provide insights from a physician's viewpoint. Conclusions drawn should be treated cautiously,

as follows from the introductory character of this study. Estimates provided may be inconsistent with medical records [9]. Assessing adherence of physicians is difficult, and is directly incomparable between studies due to a lack of standardization in assessments [23]. The questionnaire we used was not designed to assess adherence alone, but was developed in the perspective of RA management according to guidelines. The population is likely representative of Polish rheumatologists due to the random quota sampling selection of outpatient clinics and then of rheumatologists. However, quota sampling was necessary for 30% of the research sample during recruitment. Notably, 28% of specialists were otherwise employed in centers with access to biologic treatment, and, therefore, potentially had experience with recruitment to bDMARD reimbursement programs.

In conclusion, nonconformity with evidence-based recommendations is centered on frequency and applied measure of disease activity monitoring, time to DMARD initiation, and duration of GC treatment. Difficulties in the optimal management of patients stem from a variety of non-medical factors.

Acknowledgments

The research was funded by Roche Polska Sp. z o.o., Warsaw, Poland. We would like to express our thanks to all the rheumatologists and interviewers involved in the research. Medical writing, professional editing and language assistance was provided by Proper Medical Writing, Warsaw Poland and sponsored by Roche Polska Sp. z o.o. Anna Juś is a current employee of Amgen Biotechnology Sp. z o.o., Warsaw, Poland.

Conflict of interest

The authors declare no conflict of interest.

References

1. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. *N Engl J Med* 2003; 348: 2635-45.
2. Borkowski T, Golabek T, Chlosta PL, Borkowski A. Evaluation and management of male lower urinary tract symptoms: treatment patterns and guidelines in a correlation study among Polish urology consultants. *Arch Med Sci* 2015; 11: 1340-51.
3. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis* 2016; 75: 3-15.
4. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis* 2017; 76: 960-77.
5. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TI-

- CORA study): a single-blind randomised controlled trial. *Lancet* 2004; 364: 263-9.
6. Rantalaiho V, Kautiainen H, Korpela M, et al. Physicians' adherence to tight control treatment strategy and combination DMARD therapy are additively important for reaching remission and maintaining working ability in early rheumatoid arthritis: a subanalysis of the FIN-RACo trial. *Ann Rheum Dis* 2014; 73: 788-90.
 7. Kuusalo L, Puolakka K, Kautiainen H, et al. Impact of physicians' adherence to treat-to-target strategy on outcomes in early rheumatoid arthritis in the NEO-RACo trial. *Scand J Rheumatol* 2015; 44: 449-55.
 8. Littlejohn G, Roberts L, Arnold M, et al. A multi-center, observational study shows high proportion of Australian rheumatoid arthritis patients have inadequate disease control. *Int J Rheum Dis* 2013; 16: 532-8.
 9. Gvozdenović E, Allaart CF, van der Heijde D, et al. When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS). *RMD Open* 2016; 2: e000221.
 10. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. *Ann Rheum Dis* 2016; 75: 3-15.
 11. Krüger K, Karberg K. "Treat-To-Target" aus der Sicht der niedergelassenen Rheumatologie. *Z Rheumatol* 2011; 70: 664-9.
 12. Haraoui B, Bensen W, Bessette L, et al. Treating rheumatoid arthritis to target: a Canadian physician survey. *J Rheumatol* 2012; 39: 949-53.
 13. Kaneko Y, Koike T, Oda H, et al. Obstacles to the implementation of the treat-to-target strategy for rheumatoid arthritis in clinical practice in Japan. *Mod Rheumatol* 2015; 25: 43-9.
 14. Haraoui B, Smolen JS, Aletaha D, et al. Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire. *Ann Rheum Dis* 2011; 70: 1999-2002.
 15. Manara M, Bianchi G, Bruschi E, et al. Adherence to current recommendations on the use of methotrexate in rheumatoid arthritis in Italy: results from the MARI study. *Clin Exp Rheumatol* 2016; 34: 473-9.
 16. Batko B, Stajszczyk M, Świerkot J, et al. Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. *Arch Med Sci* 2019; 15: 134-40.
 17. Ma K, Li L, Liu C, et al. Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis. *Arch Med Sci* 2019; 15: 33-54.
 18. Tłustochowicz M, Śliwczyński AM, Brzozowska M, et al. Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014. *Arch Med Sci* 2018; 14: 569-71.
 19. Paulshus Sundlisæter N, Aga AB, Olsen IC, et al. Clinical and ultrasound remission after 6 months of treat-to-target therapy in early rheumatoid arthritis: associations to future good radiographic and physical outcomes. *Ann Rheum Dis* 2018; 77: 1421-5.
 20. Barhamain AS, Magliah RF, Shaheen MH, et al. The journey of rheumatoid arthritis patients: a review of reported lag times from the onset of symptoms. *Open Access Rheumatol Res Rev* 2017; 9: 139-50.
 21. Haskard Zolnieriek KB, DiMatteo MR. Physician communication and patient adherence to treatment. *Med Care* 2009; 47: 826-34.
 22. Lesuis N, van Vollenhoven RF, Akkermans RP, et al. Rheumatologists' guideline adherence in rheumatoid arthritis: a randomised controlled study on electronic decision support, education and feedback. *Clin Exp Rheumatol* 2018; 36: 21-8.
 23. Wabe N, Wiese MD. Treating rheumatoid arthritis to target: physician and patient adherence issues in contemporary rheumatoid arthritis therapy. *J Eval Clin Pract* 2017; 23: 486-93.
 24. Vermeer M, Kuper HH, Bernelot Moens HJ, et al. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort. *Arthritis Res Ther* 2012; 14: R254.
 25. Schoels M, Aletaha D, Smolen JS, et al. Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. *Ann Rheum Dis* 2010; 69: 575-8.
 26. Tugnet N, Pearce F, Tosoundou S, et al. To what extent is NICE guidance on the management of rheumatoid arthritis in adults being implemented in clinical practice? A regional survey. *Clin Med* 2013; 13: 42-6.
 27. Bianchi G, Caporali R, Todoerti M, Mattana P. Methotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administration. *Adv Ther* 2016; 33: 369-78.
 28. Bączyk G, Kozłowska K. The role of demographic and clinical variables in assessing the quality of life of outpatients with rheumatoid arthritis. *Arch Med Sci* 2018; 14: 1070-9.
 29. Malinowski KP, Kawalec PP, Moćko P. Indirect costs of absenteeism due to rheumatoid arthritis, psoriasis, multiple sclerosis, insulin-dependent diabetes mellitus, and ulcerative colitis in 2012: a study based on real-life data from the Social Insurance Institution in Poland. *Expert Rev Pharmacoecon Outcomes Res* 2016; 16: 295-303.